Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Dermatology Drugs in Phase I Clinical Development in UNITED STATES

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Histogen

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Duphat

              Participation Not Confirmed

              Update your events

              Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

              Contact the Supplier

              Lead Product(s): HST 001

              Therapeutic Area: Dermatology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Conatus Pharmaceuticals

              Deal Size: $135.1 million Upfront Cash: Undisclosed

              Deal Type: Merger January 28, 2020

              Details:

              Proposed merger creates regenerative medicine company with three clinical-stage product candidates and combined company capitalization expected to support operations into 2021.

              Evelo Biosciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Duphat

              Participation Not Confirmed

              Update your events

              Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline t...

              Contact the Supplier

              Lead Product(s): EDP1815

              Therapeutic Area: Dermatology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2020

              Details:

              Evelo has agreed upon the design of the EDP1815 Phase 2 clinical trial with global regulatory agencies. The dose ranging study will evaluate three doses of EDP1815 versus placebo in 180 individuals.

              PharmaCompass__DigitalAd